Stockreport

Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension

Alnylam Pharmaceuticals, Inc.  (ALNY) 
Last alnylam pharmaceuticals, inc. earnings: 2/6 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: investors.alnylam.com/investor-overview
PDF – Study Met Primary Endpoint Demonstrating Clinically Significant Additive Reductions in Ambulatory Systolic Blood Pressure of Up to 12.1 mmHg Across Three Independent S [Read more]